급성 골수성 백혈병(AML) : 파이프라인 리뷰

※ 이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

급성 골수성 백혈병(AML)은 급성 골수 아구성 백혈병으로도 알려져 있으며, 혈액과 골수를 침범하는 질환입니다. 미숙한 백혈구가 골수에 축적되면서 정상적인 혈액세포의 생성을 방해하게 됩니다. 이러한 세포는 혈액 속에 들어가 전신에 퍼집니다. 증후는 피로감, 발열, 출혈, 호흡곤란, 체중 감소 등입니다. 관련된 소인으로는 방사선이나 화학물질 노출과 흡연 등이 있습니다. 어느 특정 혈액질환 때문에 AML 이외의 질환도 발병할 수 있습니다. 화학요법, 수혈, 이식, 약물요법 등의 치료법이 있습니다.

급성 골수성 백혈병(AML: Acute Myelocytic Leukemia) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

급성 골수성 백혈병(AML, 급성골수아구성백혈병) 개요

치료제 개발

기업에서 개발중인 치료제

대학/기관에서 연구중인 치료제

파이프라인 제품 개요

기업에서 개발중인 제품

대학/기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

치료제 평가

치료제 개요

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

List of Tables

• Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2018
• Number of Products under Development by Companies, H1 2018
• Number of Products under Development by Universities/Institutes, H1 2018
• Products under Development by Companies, H1 2018
• Products under Development by Universities/Institutes, H1 2018
• Number of Products by Stage and Target, H1 2018
• Number of Products by Stage and Mechanism of Action, H1 2018
• Number of Products by Stage and Route of Administration, H1 2018
• Number of Products by Stage and Molecule Type, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics SA, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AlfaSigma SpA, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corp, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amplia Therapeutics Pty Ltd, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018

List of Figures

• Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2018
• Number of Products under Development by Companies, H1 2018
• Number of Products under Development by Universities/Institutes, H1 2018
• Number of Products by Top 10 Targets, H1 2018
• Number of Products by Stage and Top 10 Targets, H1 2018
• Number of Products by Top 10 Mechanism of Actions, H1 2018
• Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
• Number of Products by Top 10 Routes of Administration, H1 2018
• Number of Products by Stage and Top 10 Routes of Administration, H1 2018
• Number of Products by Top 10 Molecule Types, H1 2018
• Number of Products by Stage and Top 10 Molecule Types, H1 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 16, 120, 105, 7, 171, 24 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 18, 16, 1, 35 and 18 molecules, respectively.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).

• The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

• The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.

• The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

• The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)

Reasons to buy:

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

• Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).

• Classify potential new clients or partners in the target demographic.

• Develop tactical initiatives by understanding the focus areas of leading companies.

• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

• Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.

• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

• Table of Contents
• Introduction
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
• Appendix